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ABSTRACT 
Objective: This is an in vitro experimental study designed to analyze the role of alternative splicing of mRNA in the apoptotic process of the cancer 
cells. Here we induced apoptosis in the glioblastoma multiforme (GBM) T-98G cell line to obtain a better understanding in the regulation of mRNA 
expression of the soluble Tumor Necrosis factor-related Apoptosis-Inducing Ligand (sTRAIL) gene.  
Methods: Cells were induced to undergo apoptosis by treatment with rotenone at 10, 20 and 40 µM for 6 h. Dimethylsulphoxide (DMSO) was used 
to dissolve rotenone and as a negative control. The morphology of the GBM-T98G cells was viewed with an inverted microscope. DNA, RNA and 
protein extractions were performed to analyse apoptotic DNA fragmentation by a DNA laddering assay, a quantitative real-time reverse 
transcriptase-polymerase chain reaction (qRT-PCR) for TRAIL mRNA expression and ELISA for caspase-9 protein expression. Electrophoresis was 
also performed on TRAIL complementary DNA (cDNA) produced from TRAIL qRT-PCR mRNA.  
Results: Nucleosomal DNA degradation was confirmed by DNA laddering, whereas the TRAIL melting curve and the cDNA electrophoresis showed a 
shift in the balance of the TRAIL mRNA isoform to the pro-apoptotic mRNA isoform, in conjunction with a significant increase in expression of 
TRAIL mRNA and caspase-9 protein.  
Conclusion: These findings indicate the regulation of apoptotic events at the level of TRAIL mRNA expression, as indicated by the shift in the 
balance of mRNA expression of the TRAIL isoform towards the pro-apoptotic isoform. 
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Glioblastoma multiforme (GBM) is the most aggressive and invasive 
malignant subset of brain tumours and is associated with dismal 
prognosis [1]. The standard first-line treatment for glioblastoma 
includes surgery, followed by focal fractionated radiotherapy with 
concomitant and adjuvant administration of the alkylating 
chemotherapy temozolomide. The addition of temozolomide 
significantly improves the median 2-and 5 y survival when compared 
to radiotherapy alone in patients with newly diagnosed glioblastoma. 
However, regardless of treatment, glioblastoma patients have a poor 
prognosis, with a median survival of 14.6 mo [1, 2]. As with many 
cancers, malignant gliomas show resistance to apoptosis—a 
characteristic that underlies both tumourigenesis and the inherent 
resistance of cancer cells to radiotherapy and chemotherapy. 
Therefore, a full understanding of the cell death mechanism and the 
genetic regulation behind it is obviously of great medical interest. 
Apoptosis can be induced by rotenone (C23H22O6), a plant compound 
derived from species of the Leguminosae family. Rotenone is a lipophilic 
compound, so it readily crosses the blood-brain barrier. Rotenone also 
shows neurotoxic properties because it creates oxidative stress by 
increasing the production of reactive oxygen species (ROS) in the 
mitochondria [3, 4]. Experimentally, rotenone is used primarily as a 
mitochondrial complex 1 inhibitor to induce the release of cytochrome C 
and initiate apoptosis through the intrinsic apoptotic pathway.  
Apoptosis is an ordered and highly selective cellular process that 
occurs in both physiological and pathological conditions. It occurs by 
two main pathways: the intrinsic apoptotic pathway, which involves 
mitochondria and the formation of apoptosome multi-protein 
complexes of cytochrome-C, apaf-1 and caspase-9, and the extrinsic 
apoptotic pathway, which can be initiated by the association of death 
receptors with the tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL). This ligand-receptor association activates the protein 
initiator caspase-8 to propagate the apoptosis signal by direct cleavage 
of downstream effector caspases to the executor protein caspase-3. 
Crosstalk also occurs from the extrinsic apoptotic pathway through 
Bid, a Bcl-2 family protein with a BH3 domain, which translocates to 
the mitochondria and triggers the intrinsic apoptotic pathway [5].  
The final process of apoptosis is characterized by the occurrence of 
two stages of DNA degradation. The first is the breakdown of DNA 
into pieces 50–300K base pairs (bp) in size, followed by 
internucleosomal cleavage by the enzyme caspase-dependent DNase 
(CAD) to form multiple oligonucleosomes of 180–200 bp. These 
cleavages result in the typical DNA ladder pattern observed in 
agarose electrophoresis gels [5, 6]. 
In humans, TRAIL is encoded by genes consisting of five exons and 
four introns on chromosome 3q26.31. TRAIL is produced 
physiologically as part of the body’s defensive immune surveillance 
mechanism that guards against the presence of cancer cells but 
disregards normal tissues [7, 8]. TRAIL is a transmembrane protein, 
and its extracellular domain contains the C terminal that can be 
cleaved by proteolytic enzymes to generate soluble TRAIL (sTRAIL). 
TRAIL has five types of receptors, including two death receptors 
(DR4 and DR5) that have an intracellular death domain that induces 
apoptosis. The other three receptors are two decoy receptors (DcR1 
and DcR2) and one osteoprotegerin receptor (OPG), which does not 
induce apoptosis but instead acts as a negative regulator of TRAIL.  
Unlike normal cells, most malignant cells do not express the decoy 
receptors and are therefore sensitive to TRAIL. This feature of 
TRAIL, combined with its antitumor and anti-metastatic properties, 
forms the basis of current phase-2 clinical trials using monoclonal 
antibodies targeting DR4 and DR5 in various cancers, including 
glioblastoma multiforme. Unfortunately, the results are not yet 
satisfactory, as drug resistance persists due to immune escape by 
cells undergoing the transformation into malignancies [9–12]. The 
TRAIL gene is known to be tightly regulated through genetic and 
epigenetic mechanisms, including the expression of the TRAIL 
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isoforms α, β, γ and δ, which are functionally different. The full-
length TRAIL α has three splice variants: the one that lacks exon 3 is 
TRAIL β and the one that lacks exons 2 and 3 other is TRAIL γ. The 
TRAIL δ variant lacks exons 3 and 4. The loss of exon 3 causes a 
frameshift mutation that results in ectopic expression of the 
extracellular domain and the loss of the pro-apoptotic functionality 
of TRAIL [8, 13]. 
MATERIALS AND METHODS 
Cell culture and rotenone treatment 
The human glioblastoma multiforme T-98G cell line was grown as a 
monolayer culture in Dulbecco’s Modified Eagle’s Medium-high glucose 
(Gibco®) with 10% foetal bovine serum (FBS) supplemented with 1% 
penicillin-streptomycin and 1% amphotericin-B at 37 °C in 5% CO2 in 
air. Rotenone (Sigma Aldrich USA) was dissolved in dimethylsulphoxide 
(DMSO) and used to induce apoptosis at a dosages of 10, 20 and 40 µM; 
cells treated with DMSO served as a negative control. After a 6 h 
incubation, the cells were observed with an inverted microscope at 200× 
optical magnification. The cell were then collected and lysed for further 
analysis. 
Isolation of DNA, RNA and protein 
Tripure Isolation Kit® (Roche) was used to isolate the DNA, RNA 
and protein from the sample. The procedures of isolation followed 
the protocols provided in the kit. A bovine serum albumin (BSA) 
standard protein curve was prepared for the determination of total 
protein concentrations [14]. 
DNA ladder assay 
Nucleosomal DNA degradation was identified based on the formation 
of a DNA ladder. The Apoptotic DNA Ladder Kit (Abcam®) was used to 
detect apoptosis of GBM T-98G cells in control and treated samples by 
following the instructions contained in the kit. 
Caspase-9 protein expression assay 
An indirect sandwich ELISA method was used to determine the 
caspase-9 concentration using a Human Caspase-9 Platinum ELISA 
Kit (eBioscience®). A caspase-9 standard protein curve was made 
determination of caspase-9 concentration. 
Soluble trail (sTRAIL) gene expression  
Complementary DNA for sTRAIL analysis was synthesised from 200ng of 
total RNA by a quantitative real-time reverse transcriptase-polymerase 
chain reaction (qRT-PCR) using the One-step qRT-PCR Kit 
(KAPATMSYBR®FAST). The melting curve and relative expression of 
sTRAIL were evaluated by qRT-PCR using specific oligonucleotide 
primers: 5’-TGCGTGCTGATCGTGATCTT-3’ (forward primer) and 5’-
TTGGAGTCTTTCTAACGAGCTG-3’ (reverse primer). The primer was 
design based on accession number NM 001190942.1 obtained from the 
RefSeq NCBI Gene Bank. A non-template control was performed for each 
experiment, establishing the absence of genomic contamination in the 
sample. The 18S rRNA was used as a reference gene (house-keeping 
gene) using primers 5’-AAACGGCTACCACATCCAAG-3’ (forward) and 5’-
CCTCCAATGGATCCTCGTTA-3’ (reverse). Each experiment was run in 
triplicate. The results of cDNA amplification were represented by Ct 
values calculated using the Livak method as relative mRNA expression 
(compared with the control) [15]. 
Data analysis using the 2-ΔΔCt method 
The corresponding cDNA synthesized from each sample was 
subjected to qRT-PCR. The data were analyzed using the equation 
described by Livak [15] as follows:  
Ratio of target gene expression = 2-ΔΔCt  
Where the threshold cycle value (Ct) indicates the fractional number 
at which the amount of amplified target reaches a fixed threshold. 
The ΔCt was the average Ct of the target gene minus the average Ct 
of the reference gene, and the ΔΔCt was the average ΔCt of the 
treated cells minus the average ΔCt of the untreated cells. 
Electrophoresis of cDNA sTRAIL  
The amplified cDNA fragments produced from qRT-PCR of sTRAIL 
mRNA were visualised by gel electrophoresis. 
Statistical analysis  
Significant differences were statistically analysed using a 
nonparametric Mann-Whitney test. Differences of P<0.05 were 
considered statistically significant. 
 
 
Fig. 1: (a) T-98G cell culture treated with 10 µM rotenone shows membrane budding changes (insert, red arrows); (b) T-98G cell culture 
treated with 20 µM rotenone shows more membrane budding changes. (insert, red arrows); (c) T-98G cell line treated with 40µM 
rotenone shows alterations in cell shape accompanied by cell membrane budding (insert) 
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RESULTS 
Observation of the cell morphology showed membrane budding 
changes in glioblastoma T-98G cells treated with 10 µM rotenone 
(fig. 1a). Membrane budding changes and cell breakdown were 
observed in cells treated with 20 µM rotenone, but the cell 
membranes remained intact (fig. 1b). Cells treated with 40 µM 
rotenone were swollen, indicating that the cell membranes were no 
longer intact; these hydropic degeneration picture leads to the 
process of necrotic degradation (fig. 1c). 
Nucleosomal DNA degradation in the form of DNA laddering appeared 
clearly in the samples treated with 10 and 20µM rotenone. The ladder 
began to diminish in samples treated with 40 µM rotenone (fig. 2). The 
control samples treated with DMSO alone were provided with a solvent 
volume equivalent to that administered the R40 treatment. 
 
 
Fig. 2: The DNA ladder indicating internucleosomal DNA fragmentation due to apoptosis 
 
The analysis of caspase-9 protein revealed increased expression in 
the cells treated with 20 µM rotenone (fig. 3). This result was 
consistent with the expression of sTRAIL mRNA, which also showed 
a significant increase in response to 20 µM rotenone (fig. 4). 
 
 
Fig. 3: Relative expression of caspase-9 in T98G cells treated with rotenone or DMSO alone. Treatment with 20 µM rotenone increased 
caspase-9 expression. * p=0.05 
 
 
Fig. 4: Relative expression of mRNA-TRAIL in T98G cells treated with rotenone or DMSO alone. The increase in TRAIL expression in 20 µM 
treated cells was statistically significant. * p<0.05 
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The sTRAIL melting curve analysis showed two similar melting 
wave peaks in the control sample. This changed to a single 




Fig. 5: (a) Melting curve with two peaks for the qRT-PCR of the control sample (DMSO alone); (b) Shifting of the melting curve peak for the 
qRT-PCR of the sample treated with 10 µM rotenone; (c) Melting curve showing a single peak for the qRT-PCR of the sample treated with 
20 µM rotenone 
 
 
Fig. 6: Two isoforms of TRAIL, with the short band dominant in the cell control treatment (B) and sample treated with DMSO alone (D). 
The sample treated with 10 µM rotenone (R10) shows a shift towards the longer isoform. The band for the longer isoform becomes more 
intense in the sample treated with 20 µM rotenone (R20) and the band intensity of the shorter isoform decreases. The long isoform band 
also begins to disappear in the sample treated with 40 µM rotenone (R40). This phenomenon revealed a transition of expression from the 
anti-apoptotic isoform to the pro-apoptotic isoform, as well as the end of the apoptotic process and its replacement with necrosis and a 
loss of gene expression due to DNA degradation 
 
The phenomenon above revealed a transition of expression from the 
anti-apoptotic isoform to the pro-apoptotic isoform, as well as the 
end of the apoptotic process and its replacement with necrosis and a 
loss of gene expression due to DNA degradation.  
DISCUSSION 
One form of gene regulation is the alternative splicing that occurs 
during the pre-mRNA maturation process. This splicing process 
involves the addition or removal of specific exons of a gene so that 
the mature mRNA translocated to the ribosome carries different 
instructions for protein synthesis. The isoform proteins produced 
through alternative splicing play an essential role in several 
physiological processes involved in cell development, including the 
regulation of apoptotic mechanisms. Cells undergoing malignant 
transformation are known to have the ability to interfere with this 
splicing process, thereby affecting the cell’s ability to undergo 
apoptosis [16]. 
As one of the natural cytokines produced by immune cells such as T 
cells and natural killer (NK) cells to induce apoptosis in immune 
surveillance mechanisms, the anti-tumor potential of TRAIL is 
undoubtedly. However, phase-2 clinical studies based on the use of 
recombinant human TRAIL or their agonistic monoclonal antibodies 
against DR4 and DR5 show less encouraging results even though 
these death receptors are overexpressed by cancer cells [17]. One of 
the basics of resistance is the ability of cancer cells to regulate gene 
expression by alternative splicing of pre-mRNA. The term “better to 
die than be wrong” has been rearranged in cancer cells by the 
expression of isoform proteins which support anti-apoptotic 
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properties. As shown in this study, GBM cells predominantly express 
the non-apoptotic isoforms of sTRAIL. This regulatory mechanism 
can be changed by rotenone, which shifts the regulation of sTRAIL 
gene expression towards the pro-apoptotic isoform.  
CONCLUSION 
This study demonstrated the beneficial role of rotenone in the 
process of apoptosis, specifically as a regulator of sTRAIL gene 
expression at the level of mRNA. This finding underlines the 
importance of understanding about the regulation of genetic 
expression in various cases of resistance to cancer targeted therapy. 
Going forward, the use of specific gene expression regulatory 
substances that work synergistically with anti-cancer drugs can be 
an option for therapeutic modalities in cancer. 
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